Scribe Therapeutics

IPO

Rewriting medicine with molecular engineering

Alameda, United States · Founded 2018 · $145.0M raised

Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$145.0M
Last Round
$25.0M GrantJun 2026
Rounds
3

About

Scribe Therapeutics is a molecular engineering company developing best-in-class CRISPR-based genetic medicines, founded by Nobel Prize-winning CRISPR pioneer Jennifer Doudna and colleagues at UC Berkeley. The company engineers optimized in vivo CRISPR systems targeting cardiometabolic diseases, with partnerships with Eli Lilly and Sanofi and programs projected to enter the clinic in mid-2026.

Summary

Scribe Therapeutics is a Healthcare company based in Alameda, United States, founded in 2018. It has raised $145.0M in total across 3 rounds, most recently a $25.0M Grant round in Jun 2026. Investors include Andreessen Horowitz, California Institute for Regenerative Medicine (CIRM) and Avoro Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOJul 2026
$128.7M

Sign up to see all 4 rounds

Series A through IPO — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Scribe Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/scribe-therapeutics"><img src="https://indexed.vc/api/badge/company/scribe-therapeutics" alt="Scribe Therapeutics on Indexed.vc" width="260" height="76" /></a>